Main characteristics, comorbidities, and concomitant medications of the patients who have been enrolled in the INTERIM study
| No. of patients | 76 |
| Gender, M/F, n | 41/35 |
| Age at enrollment, y, median (range) | 72 (65-83) |
| Patients >80 y old, n (%) | 8 (11%) |
| Time from diagnosis, mo, median (range) | 64 (25-98) |
| Sokal risk (at diagnosis), n (%) | |
| Low (<0.80) | 25 (33%) |
| Intermediate (0.80–1.20) | 42 (55%) |
| High (>1.20) | 9 (12%) |
| IM therapy duration, mo | |
| Median (range) | 60 (24-94) |
| No. of patients with more than 48 mo (%) | 51 (67%) |
| IM dose, mg, median | 400 |
| No. of patients at 200 mg (%) | 2 (3%) |
| No. of patients at 300 mg (%) | 11 (14%) |
| No. of patients at 400 mg (%) | 62 (81%) |
| No. of patients at 600 mg (%) | 1 (1%) |
| Patients with comorbidities, n (%) | 68 (89%) |
| Cardiovascular | 55 (72%) |
| Prostatic | 14 (18%) |
| Gastrointestinal | 14 (18%) |
| Kidney | 12 (16%) |
| Arthritis | 7 (9%) |
| Respiratory | 6 (8%) |
| Neurological | 6 (8%) |
| Diabetes mellitus | 5 (7%) |
| Thyroid | 5 (7%) |
| Other | 20 (26%) |
| Patients with concomitant medications, n (%) | 54 (71%) |
| 1-2 drugs | 20 (26%) |
| 3-4 drugs | 24 (31%) |
| >4 drugs | 10 (13%) |
| Cy3A4 drugs metabolized | 21 (28%) |
| No. of patients | 76 |
| Gender, M/F, n | 41/35 |
| Age at enrollment, y, median (range) | 72 (65-83) |
| Patients >80 y old, n (%) | 8 (11%) |
| Time from diagnosis, mo, median (range) | 64 (25-98) |
| Sokal risk (at diagnosis), n (%) | |
| Low (<0.80) | 25 (33%) |
| Intermediate (0.80–1.20) | 42 (55%) |
| High (>1.20) | 9 (12%) |
| IM therapy duration, mo | |
| Median (range) | 60 (24-94) |
| No. of patients with more than 48 mo (%) | 51 (67%) |
| IM dose, mg, median | 400 |
| No. of patients at 200 mg (%) | 2 (3%) |
| No. of patients at 300 mg (%) | 11 (14%) |
| No. of patients at 400 mg (%) | 62 (81%) |
| No. of patients at 600 mg (%) | 1 (1%) |
| Patients with comorbidities, n (%) | 68 (89%) |
| Cardiovascular | 55 (72%) |
| Prostatic | 14 (18%) |
| Gastrointestinal | 14 (18%) |
| Kidney | 12 (16%) |
| Arthritis | 7 (9%) |
| Respiratory | 6 (8%) |
| Neurological | 6 (8%) |
| Diabetes mellitus | 5 (7%) |
| Thyroid | 5 (7%) |
| Other | 20 (26%) |
| Patients with concomitant medications, n (%) | 54 (71%) |
| 1-2 drugs | 20 (26%) |
| 3-4 drugs | 24 (31%) |
| >4 drugs | 10 (13%) |
| Cy3A4 drugs metabolized | 21 (28%) |
All patients were aged ≥65 years and were in CCgR for at least 2 years.